Kiniksa Pharmaceuticals International, plc KNSA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's accrued expenses?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accrued expenses of $20.69M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's accrued expenses changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accrued expenses increased by 21.1% year-over-year, from $17.09M to $20.69M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accrued expenses?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's accrued expenses has grown at a 259.2% compound annual growth rate (CAGR), from $37K to $22.13M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.